Supervivencia global al pacientes con mieloma múltiple tratados con y sin trasplante autólogo
Fecha
2022
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
El mieloma múltiple es una neoplasia maligna que representa aproximadamente el 10 % de las neoplasias malignas cuya incidencia aumenta constantemente con la edad y alcanza su punto máximo entre los 50 y los 70 años. Es una enfermedad incurable pudiendo tratarse para reducir el dolor y el daño a los órganos, mejorar la calidad de vida y prolongar la supervivencia del paciente. Objetivo: Determinar la supervivencia global en pacientes con Mieloma Múltiple tratados con o sin trasplante autólogo atendidos en el Instituto Oncológico Nacional Dr. Juan Tanca Marengo de Guayaquil durante el periodo 2009-2019. Metodología: investigación cuantitativa con diseño no experimental, de corte transversal, tipo descriptivo, donde se estudiaron 100 historias clínicas evaluando los datos demográficos, comorbilidades, tratamiento y determinar supervivencia global. Resultados: La edad destacó en pacientes de 56-65 años 31%, del sexo masculino (52%). Comorbilidades: HTA (40%), Diabetes (14%), Hipotiroidismo (10%), Insuficiencia renal (8%). Todos los pacientes recibieron tratamiento de primera línea, solo el 35% recibieron segunda línea y el 20% recibieron TPH. Respuesta: 48% completa, 37% parcial y 15% sin respuesta, 18% de recaída el 43% fallecieron. Sobrevida Global: 65% en pacientes con TPH teniendo un promedio de vida de 100 meses y 57% sin TPH con promedio de supervivencia de 65 meses. Conclusiones: Los pacientes que recibieron TPH poseen un índice de sobrevida global mayor (100 meses) en comparación con los pacientes sin TPH (65 meses). Esto demuestra la eficacia del TPA como tratamiento que prolonga significativamente la supervivencia de los pacientes con Mieloma múltiple.
Multiple myeloma is a malignant neoplasm that represents approximately 10% of malignancies whose incidence increases steadily with age and peaks between 50 and 70 years of age. It is an incurable disease and can be treated to reduce pain and organ damage, improve quality of life and prolong patient survival. Objective: To determine the overall survival in patients with Multiple Myeloma treated with or without autologous transplant treated at the Dr. Juan Tanca Marengo National Oncology Institute in Guayaquil during the period 2009-2019. Methodology: Quantitative research with a non-experimental design, cross-sectional, descriptive type, where 100 medical records were studied, evaluating demographic data, comorbidities, treatment and determining overall survival. Results: The age stood out in patients of 56-65 years 31%, male (52%). Comorbidities: hypertension (40%), diabetes (14%), hypothyroidism (10%), renal failure (8%). All patients received first line treatment, only 35% received second line, and 20% received TPH. Response: 48% complete, 37% partial and 15% no response, 18% relapse, 43% died. Overall Survival: 65% in patients with TPH having a mean lifespan of 100 months and 57% without TPH with a mean survival of 65 months. Conclusions: Patients who received TPH have a higher overall survival rate (100 months) compared to patients without TPH (65 months). This demonstrates the efficacy of TPA as a treatment that significantly prolongs the survival of patients with multiple myeloma.
Multiple myeloma is a malignant neoplasm that represents approximately 10% of malignancies whose incidence increases steadily with age and peaks between 50 and 70 years of age. It is an incurable disease and can be treated to reduce pain and organ damage, improve quality of life and prolong patient survival. Objective: To determine the overall survival in patients with Multiple Myeloma treated with or without autologous transplant treated at the Dr. Juan Tanca Marengo National Oncology Institute in Guayaquil during the period 2009-2019. Methodology: Quantitative research with a non-experimental design, cross-sectional, descriptive type, where 100 medical records were studied, evaluating demographic data, comorbidities, treatment and determining overall survival. Results: The age stood out in patients of 56-65 years 31%, male (52%). Comorbidities: hypertension (40%), diabetes (14%), hypothyroidism (10%), renal failure (8%). All patients received first line treatment, only 35% received second line, and 20% received TPH. Response: 48% complete, 37% partial and 15% no response, 18% relapse, 43% died. Overall Survival: 65% in patients with TPH having a mean lifespan of 100 months and 57% without TPH with a mean survival of 65 months. Conclusions: Patients who received TPH have a higher overall survival rate (100 months) compared to patients without TPH (65 months). This demonstrates the efficacy of TPA as a treatment that significantly prolongs the survival of patients with multiple myeloma.
Descripción
PDF
Palabras clave
MIELOMA MULTIPLE, NEOPLASIAS, SUPERVIVENCIA, HIPOTIROIDISMO, HOSPITAL SOLCA DE GUAYAQUIL, CANTON GUAYAQUIL, ECUADOR